Add this copy of Hematopoietic Stem Cells to cart. $100.00, good condition, Sold by Ground Zero Books, Ltd. rated 4.0 out of 5 stars, ships from Silver Spring, MD, UNITED STATES, published 1985 by Marcel Dekker, Inc.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Good. xii, [2], 379, [5] pages. Illustrations. References. Index. Ex-library with usual library markings. Some markings blacked out. This is volume 2 in the Hematology series. Hematopoietic stem cells (HSCs) are the stem cells that give rise to all the other blood cells through the process of haematopoiesis. -They are derived from mesoderm and located in the red bone marrow, which is contained in the core of most bones. HSCs give rise to both the myeloid and lymphoid lineages of blood cells. (Myeloid cells include monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, dendritic cells, and megakaryocytes or platelets. Lymphoid cells include T cells, B cells, and natural killer cells. ) The definition of hematopoietic stem cells has evolved since HSCs were first discovered in 1961. The hematopoietic tissue contains cells with long-term and short-term regeneration capacities and committed multipotent, oligopotent, and unipotent progenitors. HSCs constitute 1: 10.000 of cells in myeloid tissue. HSC studies through much of the past half century have led to a much deeper understanding. More recent advances have resulted in the use of HSC transplants in the treatment of cancers and other immune system disorders. Dr. David W. Golde was an expert in blood disorders who was chief physician at Memorial Sloan-Kettering Cancer Center in New York City. He was a hematologist and oncologist with a broad interest in blood-borne disease. In the 1980's, while on the faculty of U.C.L.A. 's medical school, he helped to isolate and purify a protein called GM-CSF, which increases the body's production of white blood cells. The protein has been used to give a boost to patients' immune systems during chemotherapy, bone-marrow transplants and other procedures. While at U.C.L.A., Dr. Golde helped discover the blood-borne leukemia virus HTLV-II, which was spreading among intravenous drug users. In 1979 he was named a professor of medicine, a position he held until 1991, when he joined Memorial Sloan-Kettering. He served as physician-in-chief there from 1996 to 2002, and continued to practice in the leukemia service there until his death. In New York, he was also a professor of medicine at Cornell University Medical College and a professor of pharmacology at Cornell's graduate school of medical sciences.
